Switch View
© Newsfile
02.09.2025
ISIN: US68764Y2072
OS Therapies, Inc
OSTX
LISTED
XASE
OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting
News Preview
Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug Administration in September 2025 New York, New York--(Newsfile Corp. - September 2, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US09073Q3039
Scinai Immunotherapeutics, Ltd.
SCNI
LISTED
XETRA
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
News Preview
JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioserv...
Themefolio
Profiler
Peergroup
© Newsfile
02.09.2025
ISIN: CA58471K2020
Medicus Pharma Ltd.
MDCX
LISTED
TSX
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
News Preview
Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunityPatrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of D...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
02.09.2025
ISIN: US04280A1007
Arrowhead Pharmaceuticals Inc
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson’s Disease, and for other additional collaboration targets that will utilize Arrowhead...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
02.09.2025
ISIN: US81726A1007
Senti Biosciences, Inc.
SNTI
LISTED
NASDAQ
Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
Live webcast presentation with Co-Founder and CEO, Dr. Timothy Lu, on September 8th at 2:00 PM ET Live webcast presentation with Co-Founder and CEO, Dr. Timothy Lu, on September 8th at 2:00 PM ET...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US9224751084
Veeva Systems Inc
VEEV
LISTED
NYSE
More Than 450 Companies Drive Speed to Market with Veeva RIM
News Preview
Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities
PLEASANTON, Calif., Sept. 2, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced more than 450 companies, including 19 of the top 20 biopharmas, have adopted Veeva RIM for regulatory information management (RIM) on a...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US9224751084
Veeva Systems Inc
VEEV
LISTED
NYSE
More Than 450 Companies Drive Speed to Market with Veeva RIM
News Preview
Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities
BARCELONA, Spain, Sept. 2, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced more than 450 companies, including 19 of the top 20 biopharmas, have adopted Veeva RIM for regulatory information management (RIM) on a un...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US9224751084
Veeva Systems Inc
VEEV
LISTED
NYSE
Mehr als 450 Unternehmen verkürzen Markteinführungszeiten mit Veeva RIM
News Preview
Erweiterte regulatorische Fähigkeiten und neue Industriepartnerschaften beschleunigen die Zusammenarbeit mit globalen Gesundheitsbehörden
BARCELONA, Spanien, 2. September 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) gab heute bekannt, dass mehr als 450 Unternehmen – darunter 19 der 20 größten Biopharmaunternehmen – Veeva RIM für das Management...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US1255091092
Cigna Group (The)
CI
LISTED
NYSE
Evernorth Health Services Announces Investment in Shields Health Solutions
News Preview
Investment Further Enhances Evernorth's Participation in Growing Market for Specialty Medicine
BLOOMFIELD, Conn., Sept. 2, 2025 /PRNewswire/ -- Evernorth Health Services ("Evernorth"), a subsidiary of The Cigna Group (NYSE: CI), today announced a $3.5 billion investment in Shields Health Solutions ("Shields" or the "Company"), a leading specialt...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US97382D3035
Windtree Therapeutics Inc
WINT
LISTED
NASDAQ
Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting
News Preview
The Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US74346N4043
Propanc Biopharma, Inc.
PPCB
LISTED
OTC
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
News Preview
Purchase of Ethereum will enhance a multi-faceted corporate strategy of cryptocurrency exposure, pharmaceutical drug development and asset acquisition....
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ISIN: US86150R1077
Stoke Therapeutics Inc
STOK
LISTED
NASDAQ
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen that support the potential for zorevunersen to be the first dise...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
02.09.2025
ISIN: US74587B1017
Pulse Biosciences Inc
PLSE
LISTED
NASDAQ
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
News Preview
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful procedures in a multicenter IRB-approved study using Pulse Biosciences’ nsPFA™ Percutaneous Electrode System for the treatment of benign thyroid nodules...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ISIN: US4622221004
Ionis Pharmaceuticals Inc
IONS
LISTED
NASDAQ
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). In the studies, olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% and a hig...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ISIN: US91307C1027
United Therapeutics Corp
UTHR
LISTED
NASDAQ
United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
News Preview
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity (FV...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ISIN: US0070021086
Adicet Bio Inc
ACET
LISTED
NASDAQ
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference being held from September...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US0758871091
Becton Dickinson and Co
BDX
LISTED
NYSE
BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative
News Preview
FRANKLIN LAKES, N.J., Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE: BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations....
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated for the treatment o...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US6294441000
NRx Pharmaceuticals, Inc.
NRXP
LISTED
NASDAQ
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital
News Preview
SOUTHAMPTON, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks to a gathering of leading family offices and family members sponsored by the Global Passion Project and Rockefeller Capital on August 28-30, 2025 in Southampton, NY. The Company’s C...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US69012T2069
Outlook Therapeutics, Inc.
OTLK
LISTED
NASDAQ
Outlook Therapeutics Requests Type A Meeting with FDA
News Preview
ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the comp...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US34960Q3074
Fortress Biotech Inc
FBIO
LISTED
NASDAQ
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chair...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US74834L1008
Quest Diagnostics Inc
DGX
LISTED
NYSE
Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index
News Preview
Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020
SECAUCUS, N.J., Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the general U.S. workforce testing positive for fentanyl in random drug tests far exceeded those in pre-employment testing, according to the 2025 Quest Diagnost...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US85916J4094
Stereotaxis Inc
STXS
LISTED
XASE
First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter
News Preview
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the world’s first procedures using MAGiC Sweep™, the first and only robotically-navigated high-density electrophysiology (EP) mappin...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US1374041093
Candel Therapeutics, Inc.
CADL
LISTED
NASDAQ
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
News Preview
NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel’s Research Advisory Board (RAB)....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US65487U1088
Nkarta Inc
NKTX
LISTED
NASDAQ
Nkarta to Participate in a September Investor Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: KYG8807B1068
Theravance Biopharma Inc
TBPH
LISTED
NASDAQ
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
DUBLIN, Sept. 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference in New York City.
Rick Winningham, CEO...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: KYG0520K1094
Ascletis Pharma Inc.
1672
LISTED
HKSE
Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
News Preview
- Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion
- On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the fourth quarter of 2025
HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascle...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US45166A1025
IDEAYA Biosciences Inc
IDYA
LISTED
NASDAQ
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
News Preview
Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the USDarovasertib is a small molecule developed for patients with uveal melanoma, a rare type of eye cancer with high unmet medical needIDEAYA will receive an upfront payment of $210 million and up to $320 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US3207031010
Calidi Biotherapeutics, Inc.
CLDI
LISTED
XASE
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced that its management will participate in th...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US3632252025
Galectin Therapeutics Inc
GALT
LISTED
NASDAQ
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York, NY....
Themefolio
Profiler
Peergroup
© Newsfile
02.09.2025
ISIN: US68764Y2072
OS Therapies, Inc
OSTX
LISTED
XASE
OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing
News Preview
All remaining holders of outstanding warrants with $1.12 per share exercise price have participated, raising $3.7 million in gross proceeds to be used to accelerate OST-HER2 commercial launch preparationsNew warrants issued have an exercise price of $3.00 per share with a forced exercise provision when the stock trades above $9.00 New York, New Yor...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ISIN: IE0005711209
ICON PLC
ICLR
LISTED
NASDAQ
ICON plc to Participate at Upcoming Investor Conferences
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Barry Balfe, COO of ICON plc, will present at the Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 1:25 pm ET and Dr. Steve Cutler, CEO of ICON plc, will participate at the Deutsche Bank 20...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ISIN: CA68617J1003
Organigram Global Inc
OGI
LISTED
NASDAQ
Organigram Global Releases Landmark Report: Legal Cannabis Added $16B to Canada’s GDP in 2024
News Preview
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), Canada’s largest cannabis company by market share, today released "High Impact, Green Growth: The Economic Footprint of Canada's Cannabis Industry," a national report done in partnership with the Business Data Lab at the Canadian Chamber of Commerce. The report, which examined figures for 2024, unde...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: KYG9390W1015
VIVA Biotech Holdings
1873
LISTED
HKSE
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
News Preview
SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine the oral potential of small molecules with the str...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US29089Q1058
Emergent BioSolutions Inc
EBS
LISTED
NYSE
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
News Preview
GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: KYG9390W1015
VIVA Biotech Holdings
1873
LISTED
HKSE
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
News Preview
SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine the oral potential of small molecules with the str...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US21900C3088
CorMedix Inc
CRMD
LISTED
NASDAQ
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
News Preview
- Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
News Preview
PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be sh...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ISIN: US68622V1061
Organon & Co
OGN
LISTED
NYSE
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
News Preview
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference pr...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US98937L1052
Zenas BioPharma, Inc.
ZBIO
LISTED
NASDAQ
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
News Preview
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease -...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US67577C1053
Ocugen Inc
OCGN
LISTED
NASDAQ
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
News Preview
MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate in both a fireside chat at the H.C. Wainwright...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US61225M1027
Monte Rosa Therapeutics Inc
GLUE
LISTED
NASDAQ
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
News Preview
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US09062X1037
Biogen Inc
BIIB
LISTED
NASDAQ
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
News Preview
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US28106W1036
Editas Medicine Inc
EDIT
LISTED
NASDAQ
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
News Preview
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US0080642061
Jade Biosciences Inc
JBIO
LISTED
NASDAQ
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
News Preview
First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US5787841007
Maze Therapeutics Inc
MAZE
LISTED
NASDAQ
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Misbah Tahir as chief financial officer (CFO), effective immediately....
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy
News Preview
HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination therapy, for the first-line treatment of advanced bili...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US91678A1079
Upstream Bio, Inc.
UPB
LISTED
NASDAQ
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
News Preview
Positive top-line results for VIBRANT Phase 2 clinical trial of verekitug in CRSwNP with once every 12 week dosing...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: US98985Y1082
Zymeworks Inc
ZYME
LISTED
NYSE
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
News Preview
VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced its d...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US14070B1017
Capricor Therapeutics, Inc.
CAPR
LISTED
NASDAQ
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
News Preview
LOS ANGELES, Sept. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: US14070B1017
Capricor Therapeutics, Inc.
CAPR
LISTED
NASDAQ
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.09.2025
ISIN: US5845073056
Medical Care Technologies Inc.
MDCE
LISTED
OTC
Medical Care Technologies Inc. (OTC PINK:MDCE) Unveils Patent-Pending AI Mental Health Tracker Targeting $400 Billion Market
News Preview
MESA, ARIZONA / ACCESS Newswire / September 2, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), an innovator in AI-powered healthcare technologies, today announced its AI Mental Health Tracker, a breakthrough solution designed to transform how anxiety, depression, and PTSD are detected and monitored. Visit the official site for more details a...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: VGG111961055
Biohaven Ltd.
BHVN
LISTED
NYSE
BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biohaven Ltd. ("Biohaven" or "the Company") (NYSE: BHVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Sec...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ISIN: SE0007464888
Karo Pharma AB
KARO
LISTED
STO
Karo Healthcare strengthens its portfolio of skin health brands in Northern Europe
News Preview
STOCKHOLM, Sept. 2, 2025 /PRNewswire/ -- Following the closing of KKR's acquisition of Karo Healthcare ("Karo") on 27 August, Karo today confirms that the agreement to acquire a portfolio of skin health brands, including ACO, has been transferred to Karo. The pending transaction was previously announced by a KKR-affiliated vehicle and Perrigo Com...
Themefolio
Profiler
Peergroup
© Newsfile
02.09.2025
ISIN: CA24463V1013
Defence Therapeutics Inc.
DTC
LISTED
CSE
Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
News Preview
Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the engagement of Amie Phinney, PhD, MBA as the Strategy & Business Advisor, effective immediately...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.09.2025
ISIN: US92919Y1029
VSee Health Inc
VSEE
LISTED
NASDAQ
VSee Health Teleradiology Expands to 25 Hospitals for an Estimated $3.0 Million Annualized Revenue
News Preview
SAN JOSE, CALIFORNIA / ACCESS Newswire / September 2, 2025 / VSee Health, Inc. (Nasdaq:VSEE), a leader in telehealth solutions, today announced the expansion implementation of 17/of 25 teleradiology. VSee health was awarded an increase to 22 hospitals by a significant vendor who recently awarded an additional 3 hospitals. VSee Health has now implem...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.09.2025
ISIN: US45408X3089
IGC Pharma, Inc
IGC
LISTED
XASE
IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada
News Preview
POTOMAC, MD / ACCESS Newswire / September 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment for agitation in Alzheimer's dementia, to a new international site at Island Health's Royal Jubilee Hospital in Victoria, British Columbia, Can...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.09.2025
ISIN: US14757U2087
CASI Pharmaceuticals, Inc.
CASI
LISTED
NASDAQ
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
News Preview
- Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations- Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 2, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: TW0004174008
OBI Pharma Inc
4174
LISTED
TWO
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
News Preview
OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology for evaluation of safety and efficacy in Cancer. OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology for evaluation of safety and efficacy in Cancer....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
